Literature DB >> 17562750

The use of atrial overdrive and ventricular rate stabilization pacing algorithms for the prevention and treatment of paroxysmal atrial fibrillation: the Pacemaker Atrial Fibrillation Suppression (PAFS) study.

Neil Sulke1, John Silberbauer, Lana Boodhoo, Nick Freemantle, Kayvan Kamalvand, Sean O'Nunain, David Hildick-Smith, Guy W Lloyd, Nikhil R Patel, Vince Paul.   

Abstract

AIMS: The PAFS study is a randomized, multicentre investigation of the effects of third generation anti-atrial fibrillation pacemaker algorithms in patients with paroxysmal atrial fibrillation (PAF). METHODS AND
RESULTS: 182 patients (72 +/- 9 years, 55% male) with at least three symptomatic episodes of PAF within prior 3 months resistant to two anti-arrhythmics were enrolled. A pacemaker-derived atrial fibrillation (AF) burden of 1-50% was required in the initial induction phase. Seventy-nine patients fulfilled these criteria and were randomized to four, month-long phases in a crossover design. Algorithm phases were 'rate soothing' on, 'ventricular rate stabilization' on, and 'All on', which included these two algorithms plus post-AF response. The algorithm phases were compared to 'All off' dual chamber universal mode (DDD 60) for the analysis. Forty-two percent of patients enrolled in the monitoring phase had no AF. The percentage of AF induced by premature atrial contractions (PACs) was significantly reduced by rate soothing from 25 to 17% (P < 0.05). There was no significant change in AF burden, AF episode number, quality of life, or symptoms with any algorithm (P = ns).
CONCLUSION: The rate-soothing algorithm by atrial overdrive pacing reduced PAC-initiated PAF. However, there was no overall change in AF burden, PAF episodes, patient symptoms, or quality of life. Forty-two percent of PAF patients did not show any AF after enrollment, suggesting that bradycardia pacing alone eliminates AF.

Entities:  

Mesh:

Year:  2007        PMID: 17562750     DOI: 10.1093/europace/eum111

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  7 in total

1.  Interatrial septum versus right atrial appendage pacing for prevention of atrial fibrillation : A meta-analysis of randomized controlled trials.

Authors:  L Zhang; H Jiang; W Wang; J Bai; Y Liang; Y Su; J Ge
Journal:  Herz       Date:  2017-07-28       Impact factor: 1.443

Review 2.  Management of atrial fibrillation in bradyarrhythmias.

Authors:  Giuseppe Boriani; Luigi Padeletti
Journal:  Nat Rev Cardiol       Date:  2015-03-17       Impact factor: 32.419

3.  The usefulness of minimal ventricular pacing and preventive AF algorithms in the treatment of PAF: the 'MinVPace' study.

Authors:  Rick A Veasey; Anita Arya; Nick Freemantle; John Silberbauer; Nikhil R Patel; Guy W Lloyd; A Neil Sulke
Journal:  J Interv Card Electrophysiol       Date:  2010-01-16       Impact factor: 1.900

4.  Electrophysiological characteristics associated with symptoms in pacemaker patients with paroxysmal atrial fibrillation.

Authors:  John Silberbauer; Rick A Veasey; Elizabeth Cheek; Nadeem Maddekar; Neil Sulke
Journal:  J Interv Card Electrophysiol       Date:  2009-07-28       Impact factor: 1.900

5.  [Atrial pacing for prevention of atrial fibrillation. Influence of septal atrial pacing, atrial overdrive and AV-delay-optimization on atrial fibrillation burden].

Authors:  M Klein; N Klein; D Pfeiffer
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2009-09

Review 6.  Advances in Cardiac Pacing: Arrhythmia Prediction, Prevention and Control Strategies.

Authors:  Mehrie Harshad Patel; Shrikanth Sampath; Anoushka Kapoor; Devanshi Narendra Damani; Nikitha Chellapuram; Apurva Bhavana Challa; Manmeet Pal Kaur; Richard D Walton; Stavros Stavrakis; Shivaram P Arunachalam; Kanchan Kulkarni
Journal:  Front Physiol       Date:  2021-12-02       Impact factor: 4.566

7.  Right atrial preference pacing algorithm in the prevention of paroxysmal atrial fibrillation in myotonic dystrophy type 1 patients: a long term follow-up study.

Authors:  Gerardo Nigro; Vincenzo Russo; Anna Rago; Andrea Antonio Papa; Alberto Palladino; Luisa Politano
Journal:  Acta Myol       Date:  2012-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.